Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›SNY›SAR439459

SAR439459

Ensayo de Sanofi en Malignant Solid Tumor (del registro, en inglés).

Fase
Fase 1
Estado
Completado
Participantes
161
previstos
Centros
34
Fin del objetivo primario
dic 2021
fecha real

Título oficial en el registro (en inglés): A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, abierto. Comenzó en jun 2017.

De principio a fin

  1. Empieza el ensayo (jun 2017)
  2. Lectura de resultados dic 2021 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Incidence of Dose Limiting Toxicities (DLTs) (Through the end of 1 or 2 cycles, total duration up to 6 weeks (for Part 1A each cycle is 2 weeks; for Part 1B each cycle is 2 or 3 weeks)) (del registro, en inglés)

Qué se prueba

Se busca determinar la dosis máxima tolerada del fármaco SAR439459 administrado por vía intravenosa en monoterapia, en adultos con tumores sólidos avanzados.

Lo que dice el documentoTo determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with advanced solid tumors. Part 1B (SAR439459 and cemiplimab combination therapy) * To determine the MTD and/or MAD of SAR439459 administered intravenously in combination with cemiplimab administered intravenously in adult patients with advanced solid tumors.

Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroPrimary Objectives: Dose escalation (Part 1) Part 1A (SAR439459 monotherapy) * To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with advanced solid tumors. Part 1B (SAR439459 and cemiplimab combination therapy) * To determine the MTD and/or MAD of SAR439459 administered intravenously in combination with cemiplimab administered intravenously in adult patients with advanced solid tumors. Dose expansion (Part 2) Part 2A (SAR439459 monotherapy) * To determine optimal dose of SAR439459 administered intravenously in adult patients with advanced melanoma who have failed a prior therapy based on anti-PD-1 (programmed cell death-1) or anti-PD-L1. Part 2B (SAR439459 and cemiplimab combination therapy) * To determine the objective response rate (ORR) of SAR439459 in combination with cemiplimab in adult patients with selected advanced solid tumors by evaluation of antitumor response according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). Secondary Objectives: * Pharmacokinetic (PK) profile SAR439459 monotherapy and combined with cemiplimab, PK profile of cemiplimab combined with SAR439459. * Immunogenicity of SAR439459 monotherapy and combined with cemiplimab. Dose escalation (Part 1) * Overall safety/tolerability profile of SAR439459 monotherapy and combined with cemiplimab. * Preliminary recommended phase 2 dose (pRP2D) of SAR439459 as monotherapy or combined with cemiplimab. Dose expansion (Part 2) * Progression free survival (PFS), time to progression (TTP), ORR, and safety of SAR439459 as monotherapy and PFS, TTP, duration of response (DOR), disease control rate (DCR) and safety in combination with cemiplimab. * To confirm the optimal dose of SAR439459 administered in combination with cemiplimab.

Sigue a SNY y recibe cada mañana en tu correo lo que haya presentado ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Más ensayos de SNY

EnsayoFaseEstadoLectura de resultados
Avalglucosidase alfa · Mini-COMETFase 2En marcha, sin reclutarsep 2019 (real)
Yellow fever vaccineFase 2En marcha, sin reclutarmay 2022 (real)
Yellow fever vaccine · VYF02Fase 2En marcha, sin reclutarjun 2022 (real)
SAR441344 IVFase 2En marcha, sin reclutarsep 2022 (real)
Meningococcal PolysaccharideFase 3En marcha, sin reclutarmar 2023 (real)
rilzabrutinib · LUMINA 2Fase 2En marcha, sin reclutarmay 2024 (real)

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT03192345), actualizada en ago 2024.